Skip to main content
SpringerLink
Log in

Gastric Adenocarcinoma

  • Chapter
  • First Online:
Surgical Oncology Manual

Abstract

Gastric cancer remains a leading cause of cancer mortality worldwide, but demonstrates wide geographic variation in its incidence. Highest incidences are observed in East Asian, East European, and Central and South American countries, where rates of gastric cancer are five- to tenfold the rates observed in Canada. In North America, the majority of patients diagnosed with gastric cancer have advanced disease at presentation. Surgical resection with negative margins and appropriate lymphadenectomy remains the mainstay of treatment for patients presenting with locoregional disease. Endoscopic resection can be considered in highly selected patients presenting with early cancers. Advances in systemic therapy for gastric adenocarcinoma have led to improved survival in both curative and palliative settings. Radiotherapy plays an important role in both the adjuvant and palliative settings. The complex multidisciplinary management of gastric cancer remains in evolution as we strive to further improve outcomes in this patient population, especially with availability of more effective treatments and new clinical trials in treatment of both locoregional and metastatic gastric cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Canadian Cancer Society. Canadian Cancer Society’s Steering Committee: Canadian Cancer Statistics 2018. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2018-EN.pdf?la=en.

  2. Kim JP. Surgical results in gastric cancer. Semin Surg Oncol. 1999;17:132–8.

    CAS  PubMed  Google Scholar 

  3. Jim MA, Pinheiro PS, Carreira H, et al. Stomach cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer. 2017;123(Suppl):4994–5013.

    PubMed  Google Scholar 

  4. Fitzgerald RCCC. Clinical implications of E-Cadherin associated hereditary diffuse gastric cancer. Gut. 2004;53:775–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Gayther SA, Gorrini’s KL, Ramos SJ, et al. Identification of germ-line E-Catherine mutations in gastric cancer families of European Origin. Cancer Res. 1998;58:4086–9.

    CAS  PubMed  Google Scholar 

  6. Seevaratnam R, Coburn N, Cardozo R, et al. A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S153–63.

    PubMed  Google Scholar 

  7. Pharoah PD, Guilford PCC. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348–53.

    CAS  PubMed  Google Scholar 

  8. van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361–74.

    PubMed  Google Scholar 

  9. Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36:873.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Rudloff U. Gastric adenocarcinoma and proximal polyposis of the stomach: diagnosis and clinical perspectives. Clin Exp Gastroenterol. 2018;11:447–59.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Worthley DL, Phillips KD, Wayte N, et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut. 2012;61(5):774–9.

    CAS  PubMed  Google Scholar 

  12. Anaya DA, Chang GJ, Rodriguez-bigas MA. Extracolonic manifestation of hereditary colorectal cancer syndrome. Clin Colon Rectal Surg. 2008;21(4):263–72.

    PubMed  PubMed Central  Google Scholar 

  13. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223.

    PubMed  PubMed Central  Google Scholar 

  14. Mankaney G, Leone P, Cruise M, et al. Gastric cancer in FAP: a concerning rise in incidence. Familial Cancer. 2017;16:371–6.

    PubMed  Google Scholar 

  15. Møller P, Seppaia TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective lynch syndrome database. Gut. 2018;67(7):1306–16.

    PubMed  Google Scholar 

  16. Vasen HF, Blanco I, Astana-Collin K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812–23.

    CAS  PubMed  Google Scholar 

  17. Tomlinson IP, Houlston RS. Peutz-Jeghers Syndrome. J Med Genet. 1997;34:1007–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105(6):1258–64.

    PubMed  Google Scholar 

  19. Gupta S, Provenzale D, Regenbogen SE, et al. NCCN guidelines ® insights: genetic/familial high-risk assessment: colorectal, version 3.2017 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2017;15:1465–75.

    CAS  PubMed  Google Scholar 

  20. Balmaña J, Balaguer F, Cervantes A, Arnold D. Familial risk-colorectal cancer: ESMO clinical practice guidelines. Ann Oncol. 2013;24(Suppl 6):vi73–80.

    PubMed  Google Scholar 

  21. Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary colorectal cancer syndromes: American society of clinical oncology clinical practice guideline endorsement of familial risk-colorectal cancer: European Society for medical oncology clinical practice guidelines. J Clin Oncol. 2015;33:209–17.

    PubMed  Google Scholar 

  22. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.

    Article  CAS  PubMed  Google Scholar 

  23. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52(24):6735–40.

    CAS  PubMed  Google Scholar 

  24. Qiu M, Cai M, Zhang D, et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med. 2013;11:58.

    PubMed  PubMed Central  Google Scholar 

  25. Chen YC, Fang WL, Wang RF, et al. Clinicopathological variation of Lauren classification in gastric cancer. Pathol Oncol Res. 2016;22(1):197–202.

    PubMed  Google Scholar 

  26. Kung PL, Gubens M, Fisher GA, Ford JM, et al. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012;30(28):3507–15.

    Google Scholar 

  27. Al-Bartan SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–708.

    Google Scholar 

  28. Cancer Genome Atlas Research Network, Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.

    Google Scholar 

  29. Sohn BH, Hwang JE, Jang HJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer. 2017. https://doi.org/10.158/1078-0432.CCR-16-2211.

  30. Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3(9):1197–203.

    PubMed  Google Scholar 

  31. Amin MB, Edge S, Greene F, et al. American Joint Committee Cancer staging manual. New York: Springer; 2017.

    Google Scholar 

  32. Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 2017;20:2017.

    Google Scholar 

  33. In H, Ravetch E, Langdon-Embry M, et al. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer. 2018;21(1):1–9.

    PubMed  Google Scholar 

  34. Seevaratnam R, Cardoso R, Mcgregor C, et al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. Gastric Cancer. 2012;15(Suppl):S3–S18.

    PubMed  Google Scholar 

  35. Cardoso R, Coburn N, Seevaratnam R, et al. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer. 2012;15(Suppl):S19–26.

    PubMed  Google Scholar 

  36. Association Gastric Cancer Association. Japanese classification of gastric carcinoma – 2nd English edition. Gastric Cancer. 1998;1(1):10–24.

    Google Scholar 

  37. Gouzi JL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg. 1989;209:162–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Mahar AL, et al. A systematic review of surgery for non-curative gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S125–37.

    PubMed  Google Scholar 

  39. Bonenkamp JJ, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–14.

    CAS  PubMed  Google Scholar 

  40. Association JGC. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.

    Google Scholar 

  41. Gotoda T. Endoscopic resection of early gastric cancer: the Japanese perspective. Curr Opin Gastroenterol. 2006;22(5):561–9.

    PubMed  Google Scholar 

  42. Daoud DC, Suter N, Durand M, et al. Comparing outcomes for endoscopic submucosal dissection between Eastern and Western countries: a systematic review and meta-analysis. World J Gastroenterol. 2018;24(23):2518–36.

    PubMed  PubMed Central  Google Scholar 

  43. Jeon MY, Park JC, Hahn KY, et al. Long-term outcomes after noncurative endoscopic resection of early gastric cancer: the optimal time for additional endoscopic treatment. Gastrointest Endosc. 2018;87(4):1003–1013.e2.

    PubMed  Google Scholar 

  44. Degiuli M, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101:23–31.

    CAS  PubMed  Google Scholar 

  45. Morgagni P, La Barba G, Colciago E, et al. Resection line involvement after gastric cancer treatment: handle with care. Updat Surg. 2018;70(2):213–23.

    Google Scholar 

  46. Bria E, De Manzoni G, Beghelli S, et al. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol. 2013;24(3):693–701.

    CAS  PubMed  Google Scholar 

  47. Songun I, Bonenkamp JJ, Hermans J, et al. Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer. Eur J Cancer. 1996;32A:433–7.

    CAS  PubMed  Google Scholar 

  48. Kim SH, Karpeh MS, Klimstra DS, et al. Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg. 1999;3:24–33.

    CAS  PubMed  Google Scholar 

  49. Ito H, Clancy TE, Osleen RT, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg. 2004;199(6):880–6.

    PubMed  Google Scholar 

  50. National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology gastric cancer. v2.2018. http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.

  51. Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):38–49.

    Google Scholar 

  52. McAuliffe JC, Tang LH, Kamrani K, et al. Prevalence of false-negative results of intraoperative consultation on surgical margins during resection of gastric and gastroesophageal adenocarcinoma. JAMA Surg. 2018;154:126.

    PubMed Central  Google Scholar 

  53. Squires MH 3rd, Kooby DA, Pawlik TM, et al. Utility of the proximal margin frozen section for resection of gastric adenocarcinoma: a 7-Institution Study of the US Gastric Cancer Collaborative. Ann Surg Oncol. 2014;21(13):4202–10.

    PubMed  Google Scholar 

  54. Stiekema J, Trip AK, Jansen EPM, et al. Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an R1 resection? Results from a Dutch cohort study. Ann Surg Oncol. 2015;22:581–8.

    PubMed  Google Scholar 

  55. Stiekema J, Trip AK, Jansen EPM, Boot H, Cats A, Ponz OB, et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol. 2014;21:1107–14.

    PubMed  Google Scholar 

  56. Rhome RM, Moshier E, Sarpel U, et al. Predictors of positive margins after definitive resection for gastric adenocarcinoma and impact of adjuvant therapies. Int J Radiat Oncol Biol Phys. 2017;98:1106–15.

    PubMed  Google Scholar 

  57. Dikken JL, Jansen EPM, Cats A, Bakker B, Hartgrink HH, Kranenbarg EMK, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28:2430–6.

    PubMed  Google Scholar 

  58. Brar S, Law C, McLeod R, et al. Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg. 2013;217(2):347–57.e1.

    PubMed  Google Scholar 

  59. Kim W, Kim HH, Han SU, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg. 2016;263:28–35.

    PubMed  Google Scholar 

  60. Kurokawa Y, Doki Y, Mizusawa J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2018;3(7):460–8.

    PubMed  Google Scholar 

  61. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.

    CAS  PubMed  Google Scholar 

  62. Knight G, Earle CC, Cosby R, TGCDSG, et al.. Neoadjuvant or adjuvant therapy for resectable gastric cancer, Evidence-based series 2–14 version 3. Toronto Cancer Care Ontario; 2011.

    Google Scholar 

  63. Lowy AM, Mansfield PF, Leach SD, et al. Laparoscopic staging for gastric cancer. Surgery. 1996;119:611–4.

    CAS  PubMed  Google Scholar 

  64. Oh CA, Bae JM, Oh SJ, et al. Long-term results and prognostic factors of gastric cancer patients with only positive peritoneal lavage cytology. J Surg Oncol. 2012;105:393–9.

    PubMed  Google Scholar 

  65. Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol. 2010;17(12):3173–80.

    PubMed  Google Scholar 

  66. Newhook TE, Agnes A, Blum M, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy is safe for patients with peritoneal metastases from gastric cancer and may Lead to gastrectomy. Ann Surg Oncol. 2019;26(5):1394–400.

    PubMed  Google Scholar 

  67. Badgwell B, Blum M, Das P, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24(11):3338–44.

    PubMed  Google Scholar 

  68. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.

    PubMed  Google Scholar 

  69. Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345:745–8.

    CAS  PubMed  Google Scholar 

  70. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.

    CAS  PubMed  Google Scholar 

  71. Xiong B, Ma L, Huang W, et al. Efficiency of bursectomy in patients with resectable gastric cancer: an updated meta-analysis. Eur J Surg Oncol. 2019;45:1483.

    PubMed  Google Scholar 

  72. Kim HI, Hur H, Kim YN, et al. Standardization of D2 lymphadenectomy and surgical quality control (KLASS-02-QC): a prospective, observational, multicenter study [NCT01283893]. BMC Cancer. 2014;14:209.

    PubMed  PubMed Central  Google Scholar 

  73. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    CAS  PubMed  Google Scholar 

  74. GASTRIC, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–37.

    Google Scholar 

  75. Al-Bartan SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastricor gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948.

    Google Scholar 

  76. Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–28.

    CAS  PubMed  Google Scholar 

  77. Slagter AE, Jansen EPM, van Laarhoven HWM, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018;18(1):877.

    PubMed  PubMed Central  Google Scholar 

  78. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73.

    CAS  PubMed  Google Scholar 

  79. Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach Tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.

    CAS  PubMed  Google Scholar 

  80. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.

    CAS  PubMed  Google Scholar 

  81. Diaz-Nieto R, Orti-Rodríguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev. 2013;(9):CD008415.

    Google Scholar 

  82. Grau JJ, Martín M, Fuster J, et al. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer. J Surg Oncol. 2003;82(4):234–40.

    CAS  PubMed  Google Scholar 

  83. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387.

    CAS  PubMed  Google Scholar 

  84. Fujita J, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–18.

    Google Scholar 

  85. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347:995–9.

    CAS  PubMed  Google Scholar 

  86. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol. 2004;30(3):303–8.

    CAS  PubMed  Google Scholar 

  88. Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163–8.

    CAS  PubMed  Google Scholar 

  89. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Surgical Oncology, University of Toronto, Toronto, ON, Canada

    Mohammadali Khorasani

  2. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Savtaj S. Brar

  3. Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

    Natalie G. Coburn

Authors
  1. Mohammadali Khorasani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Savtaj S. Brar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalie G. Coburn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Natalie G. Coburn .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Frances C. Wright

  2. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Jaime M. Escallon

  3. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Moises Cukier

  4. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Melanie E. Tsang

  5. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Usmaan Hameed

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Khorasani, M., Brar, S.S., Coburn, N.G. (2020). Gastric Adenocarcinoma. In: Wright, F., Escallon, J., Cukier, M., Tsang, M., Hameed, U. (eds) Surgical Oncology Manual. Springer, Cham. https://doi.org/10.1007/978-3-030-48363-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-48363-0_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-48362-3

  • Online ISBN: 978-3-030-48363-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation